KIR

Qualtia Alimentos Advances Supply Chain with RELEX

Retrieved on: 
Friday, February 23, 2024

Qualtia Alimentos , a Mexican food producer and subsidiary of Xignux , has chosen RELEX Solutions , provider of unified supply chain and retail planning solutions, for demand forecasting, replenishment, and production scheduling services.

Key Points: 
  • Qualtia Alimentos , a Mexican food producer and subsidiary of Xignux , has chosen RELEX Solutions , provider of unified supply chain and retail planning solutions, for demand forecasting, replenishment, and production scheduling services.
  • Qualtia Alimentos will implement RELEX across their 69 North American distribution centers, to enhance the company's supply chain from manufacturing to planning.
  • This move is part of Qualtia Alimentos's strategy to support growth and to improve digitalization of their supply chain.
  • "Choosing RELEX was a strategic decision," said Carlos López, Supply Chain Planning Director at Qualtia Alimentos.

LUNGevity Foundation Announces $1.2M in Lung Cancer Workforce Development Research Awards

Retrieved on: 
Wednesday, November 1, 2023

WASHINGTON, Nov. 1, 2023 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is proud to continue its multifaceted investment in the thoracic oncology workforce by announcing the recipients of four awards — the Career Development Award, the VA Research Scholar Award, the Health Equity and Inclusiveness Research Fellow Award, and the ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant. 

Key Points: 
  • "Progress in lung cancer research is only possible with a vibrant and diverse thoracic oncology workforce," notes Upal Basu Roy, PhD, MPH, executive director, LUNGevity Research.
  • LUNGevity Foundation is honored to partner with the Lung Cancer Initiative (LCI) to co-fund Dr. LoPiccolo's project on the genomics of young-onset lung cancer.
  • The Lung Cancer Initiative is a leading nonprofit in North Carolina that connects the lung cancer community with the research and medical community.
  • LUNGevity's 2023 VA Research Scholar Award recipient is:
    Lung cancer screening (LCS) provides an important opportunity to find lung cancer early when it is the most treatable.

Mozart Therapeutics Highlights Promising Preclinical Activity of Novel CD8 Treg Network Modulator for Treatment of Autoimmune Diseases in Presentations at IMMUNOLOGY™ 2023

Retrieved on: 
Monday, May 15, 2023

SEATTLE, May 15, 2023 /PRNewswire/ -- Mozart Therapeutics, a leading developer of CD8 Treg Modulators in autoimmune and inflammatory disease, today announced the presentation of data at the American Association of Immunologists (AAI) Annual Meeting demonstrating the potential of its lead therapeutic, a targeted, bispecific CD8 Treg modulator, as a new therapeutic treatment approach for autoimmune diseases.

Key Points: 
  • SEATTLE, May 15, 2023 /PRNewswire/ -- Mozart Therapeutics , a leading developer of CD8 Treg Modulators in autoimmune and inflammatory disease, today announced the presentation of data at the American Association of Immunologists (AAI) Annual Meeting demonstrating the potential of its lead therapeutic, a targeted, bispecific CD8 Treg modulator, as a new therapeutic treatment approach for autoimmune diseases.
  • "The CD8 Treg cell network plays a key role in autoimmune and inflammatory diseases.
  • We've demonstrated in multiple preclinical models that our lead candidate, a KIR x CD8 Modulator, specifically activates this network to help restore immune balance by selectively reducing autoreactive CD4 T cells," said Kristine Swiderek, PhD, Chief Scientific Officer at Mozart Therapeutics.
  • "These compelling findings support further advancement of this promising and broadly applicable therapeutic approach in autoimmune diseases."

Cutaneous T-Cell Lymphoma - Pipeline Insight, 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 9, 2023

The "Cutaneous T-Cell Lymphoma - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cutaneous T-Cell Lymphoma - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This "Cutaneous T-Cell Lymphoma - Pipeline Insight, 2022" report provides comprehensive insights about 25+ companies and 27+ pipeline drugs in Cutaneous T-Cell Lymphoma pipeline landscape.
  • A detailed picture of the Cutaneous T-Cell Lymphoma pipeline landscape is provided which includes the disease overview and Cutaneous T-Cell Lymphoma treatment guidelines.
  • Phase III include, Soligenix
    Cutaneous T-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Klaytn Foundation Introduces Tokenomics Optimization Proposal to Secure Sustainable & Verifiable Token Economy

Retrieved on: 
Wednesday, February 22, 2023

The Foundation looks to merge KGF and KIR, and reorganize the combined funds into the Klaytn Community Fund (KCF) and Klaytn Foundation Fund (KFF) at a 60:40 ratio.

Key Points: 
  • The Foundation looks to merge KGF and KIR, and reorganize the combined funds into the Klaytn Community Fund (KCF) and Klaytn Foundation Fund (KFF) at a 60:40 ratio.
  • KFF funds will be used to cover Foundation operational expenses, attract new GC members, and provide liquidity.
  • Both KCF and KFF funds will be managed transparently through the Klaytn Square governance portal and executed only with the approval of the GC.
  • Dr Sangmin Seo, Representative Director, Klaytn Foundation said, "To develop this proposal, the Foundation has been closely examining overall trends in the blockchain industry, having in-depth discussions with stakeholders, and seeking community feedback.

Be The Match BioTherapies® Launches Bioinformatics Consulting Services

Retrieved on: 
Wednesday, December 14, 2022

Be The Match BioTherapies , an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced its new Bioinformatics Consulting Services , which blends the unique expertise, real-world data and assets of Be The Match BioTherapies and the CIBMTR (Center for International Blood and Marrow Transplant Research).

Key Points: 
  • Be The Match BioTherapies , an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced its new Bioinformatics Consulting Services , which blends the unique expertise, real-world data and assets of Be The Match BioTherapies and the CIBMTR (Center for International Blood and Marrow Transplant Research).
  • Our Bioinformatics Consulting Services operate at the intersection of science and technology, and bridges the transition from cell culture to the clinic.
  • The new Bioinformatics Consulting Services help companies mitigate risk by using data-driven answers to make decisions that maximize clinical success and speed allogeneic therapies to market.
  • The Bioinformatics Consulting Services experts include Martin Maiers, Vice President, Research; Abeer Madbouly, Principal Bioinformatics Scientist; Michael Wright, Scientific Coordinator; Heather Stefanski, MD, PhD, Vice President, Medical Services; and Steve Devine, MD, Chief Medical Officer.

Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Retrieved on: 
Saturday, December 10, 2022

In line with previous observations, lacutamab demonstrated a favorable safety profile for patients with advanced Szary syndrome in the TELLOMAK Phase 2 preliminary analysis.

Key Points: 
  • In line with previous observations, lacutamab demonstrated a favorable safety profile for patients with advanced Szary syndrome in the TELLOMAK Phase 2 preliminary analysis.
  • The data continues to support our fast to market strategy for lacutamab in the niche setting of Szary syndrome where lacutamab was granted U.S. Fast Track designation and EU Prime designation.
  • We thank the investigators, clinical research coordinators, patients and caregivers involved in the ongoing TELLOMAK program.
  • Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro

Retrieved on: 
Tuesday, November 15, 2022

November 15, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced promising data for the Companys lead program IOS-1002.

Key Points: 
  • November 15, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced promising data for the Companys lead program IOS-1002.
  • The presented data supports IOS-1002 as a first-in-class multi-functional agent which will enter a Phase 1 trial later this year.
  • "We are excited that our lead program IOS-1002 has generated such promising non-clinical data both as a monotherapy and in combination with anti-PD-1," added Sean R. Smith, Chief Executive Officer of ImmunOs Therapeutics.
  • ImmunOs lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and activates anti-tumor responses.

Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022

Retrieved on: 
Friday, November 4, 2022

Lacutamab in patients with advanced Sezary syndrome: results from an interim analysis of the TELLOMAK phase 2 trial

Key Points: 
  • Lacutamab in patients with advanced Sezary syndrome: results from an interim analysis of the TELLOMAK phase 2 trial
    Presenter: Dr Pierluigi Porcu, Director, Division of Medical Oncology and Hematopoietic Stem Cell Transplantation, Thomas Jefferson University Hospitals, Philadelphia
    Session Name: 704.
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III
    The posters and presentation will be available on the Publications section of innate-pharma.com following the meeting.
  • Rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few efficacious and safe therapeutic options at advanced stages.
  • Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

ImmunOs Therapeutics Appoints Dr. Hilmar Ebersbach as Vice President Antibody Development and Protein Engineering

Retrieved on: 
Monday, October 17, 2022

Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA October 17, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the appointment of Dr. Hilmar Ebersbach as Vice President Antibody Development and Protein Engineering (ADPE).

Key Points: 
  • Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA October 17, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the appointment of Dr. Hilmar Ebersbach as Vice President Antibody Development and Protein Engineering (ADPE).
  • "Hilmar brings an excellent track record in protein engineering and drug discovery, especially regarding novel drug formats and conjugates.
  • "I believe that ImmunOs approach in myeloid checkpoint therapeutics is at the forefront of current scientific research," said Dr. Hilmar Ebersbach, Vice President ADPE at ImmunOs.
  • ImmunOs Therapeutics AG leverages its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases.